Stability evaluation of house dust mite vaccines for sublingual immunotherapy

Allergen-specific immunotherapy with house dust mite (HDM) allergen extracts can effectively alleviate the symptoms of allergic rhinitis and asthma. The efficacy of the immunotherapeutic treatment is highly dependent on the quality of house dust mite vaccines. This study was performed to assess the stability of house dust mite allergen vaccines prepared for sublingual immunotherapy. Lyophilized Dermatophagoides pteronyssinus (Dpt) mite bodies were the starting material for the production of sublingual vaccines in four therapeutic concentrations. The stability of the extract for vaccine production, which was stored below 4 ?C for one month, showed consistence in the protein profile in SDS PAGE. ELISA-inhibition showed that the potencies of Dpt vaccines during a 12 month period were to 65-80 % preserved at all analyzed therapeutic concentrations. This study showed that glycerinated Dpt vaccines stored at 4?C preserved their IgE-binding potential during a 12 month period, implying their suitability for sublingual immunotherapeutic treatment of HDM allergy.

Download Full-text

Method for assessing the sublingual immunotherapy with house dust mite allergens effectiveness in children with bronchial asthma and allergic rhinitis

Pediatrician (St Petersburg) ◽

10.17816/ped12435-43 ◽

2021 ◽

Vol 12 (4) ◽

pp. 35-43

Author(s):

D. S. Korostovtsev ◽

O. V. Trusova ◽

A. V. Kamaev

Keyword(s):

Allergic Rhinitis ◽

Bronchial Asthma ◽

House Dust ◽

House Dust Mite ◽

Sublingual Immunotherapy ◽

Clinical Signs ◽

Assessment System ◽

Control Group ◽

Allergen Specific Immunotherapy ◽

Dust Mite

Background. For practical health care, tools for assessing the effect of allergen-specific immunotherapy have not been developed. Aim. Approbation of the system for evaluating the effectiveness of sublingual immunotherapy with house dust mite allergens in patients with bronchial asthma with allergic rhinitis. Materials and methods. 28 cases of sublingual immunotherapy treatment in patients aged 5 to 13 years, (8,6 [6,7; 11,6]) with control in pairs-copies matched by age, sex, and asthma severity were analyzed. Thus, the study included 56 patients. Patients in the control group did not receive sublingual immunotherapy. For 1 year before the start of treatment, and for the first year of treatment, the complex of clinical signs of bronchial asthma and allergic rhinitis, the need for basic and emergency therapy was assessed. The scores were calculated for symptoms, for drugs, and a total Score of symptoms and drugs. Results. During 1 year of therapy, patients showed dynamics of the total Score from 23,32 1,21 points to 16,21 1,77 in the main group, and from 23,99 1,2 points to 20.92 2.09 in control group (p = 0.028). The greatest difference was found within medication domain. Conclusion. The developed system for assessing the symptoms and the need for medications makes it possible to show the difference between groups of patients, in favor of the sublingual immunotherapy group. For 1 year of sublingual immunotherapy therapy, a difference in the total Score dynamics and the domain of drugs was revealed between the groups. The proposed assessment system is recommended for further investigation.

Download Full-text